Statin-induced Myopathy

 Statins are commonly used drugs for lowering LDL/bad cholesterol and preventing the risk of atherosclerosis, heart disease, and stroke. Statins are also known as HMG-Coenzyme A reductase inhibitors. They work by inhibiting the rate-limiting step in cholesterol synthesis, i.e., by inhibiting the enzyme HMG-Coenzyme A reductase (needed by the liver to produce cholesterol). 

There are different types of Statins available (Lovastatin, Simvastatin, Pravastatin, Atorvastatin, Rosuvastatin, and Fluvastatin). The most potent statin is Rosuvastatin, followed by Atorvastatin.  

The CYP3A4 metabolizes Atorvastatin, Simvastatin, and Lovastatin. 

The CYP2C9 metabolizes Rosuvastatin and Fluvastatin. 

Pravastatin is not metabolized by the CYP enzymes. 


Despite the numerous benefits of Statins, there are some risks involved with the use of statins as well. One of them is Statin-induced myopathy. It is a muscle disorder characterized by muscle pain, weakness, and muscle cramps, with symptoms starting after the initiation of Statin use. If left untreated, it can progress to Rhabdomyolysis - a medical emergency in which damaged muscle breaks down rapidly, releasing harmful proteins in the bloodstream and leading to kidney damage. The management of Statin-induced myopathy includes immediate reporting of symptoms of muscle pain, weakness, and cramps, which begin after starting statins to your healthcare provider. This is followed by the analysis of Creatine Kinase levels in the blood. CK levels give an estimate of the intensity of muscle damage. Based on the CK levels, the dose of statins may be reduced, switched to a different statin, or statins may be stopped temporarily, and CK levels are monitored. The Statins may be reintroduced at a lower dose after CK levels have returned to normal, or non-statin medications may be used to lower cholesterol.


Some individuals may be at a higher risk for Statin-induced myopathy, i.e., females, the elderly, individuals with a small body frame, individuals with renal disease, diabetes, and hypothyroidism. Some drug-drug interactions may also increase the risk of statin-induced myopathy. For example, using Grapefruit juice (CYP3A4 inhibitor) along with Atorvastatin, Simvastatin, and Lovastatin (metabolized by CYP3A4) may reduce the metabolism of these statins and increase the concentration of Statins, thereby increasing the risk of statin-induced myopathy. Similarly, it is best to avoid the use of statins with Fibrates (Gemfibrozil) and other CYP3A4 inhibitors(Grapefruit juice, Amiodarone, Azoles, Ritonavir, Clarithyromycin, Erythromycin, Verapamil, Diltiazem) and CYP2C9 inhibitors (Amiodarone, Fluconazole, Metronidazole, Sulfamethoxazole).




Comments

Popular posts from this blog

Popping Painkillers. Is it safe?

Gut Health and its impact on Mental health

PCOS Epidemic